Fermentation properties and potential prebiotic activity of Bimuno® galacto-oligosaccharide (65 % galacto-oligosaccharide content) on in vitro gut microbiota parameters.
Prebiotic oligosaccharides have the ability to generate important changes in the gut microbiota composition that may confer health benefits to the host. Reducing the impurities in prebiotic mixtures could expand their applications in food industries and improve their selectivity and prebiotic effect on the potential beneficial bacteria such as bifidobacteria and lactobacilli. This study aimed to determine the in vitro potential fermentation properties of a 65 % galacto-oligosaccharide (GOS) content Bimuno® GOS (B-GOS) on gut microbiota composition and their metabolites. Fermentation of 65 % B-GOS was compared with 52 % B-GOS in pH- and volume-controlled dose-response anaerobic batch culture experiments. In total, three different doses (1, 0·5 and 0·33 g equivalent to 0·1, 0·05 and 0·033 g/l) were tested. Changes in the gut microbiota during a time course were identified by fluorescence in situ hybridisation, whereas small molecular weight metabolomics profiles and SCFA were determined by 1H-NMR analysis and GC, respectively. The 65 % B-GOS showed positive modulation of the microbiota composition during the first 8 h of fermentation with all doses. Administration of the specific doses of B-GOS induced a significant increase in acetate as the major SCFA synthesised compared with propionate and butyrate concentrations, but there were no significant differences between substrates. The 65 % B-GOS in syrup format seems to have, in all the analysis, an efficient prebiotic effect. However, the applicability of such changes remains to be shown in an in vivo trial.
1Department of Food and Nutritional Sciences,University of Reading,Reading RG6 6AP,UK.
Roberta
R
Grimaldi
2Division of Computational and Systems Medicine,Imperial College,London SW7 2AZ,UK.
Jonathan R
JR
Swann
3Clasado Research Services Ltd,Science & Technology Centre,University of Reading,Reading RG6 6BZ,UK.
Jelena
J
Vulevic
1Department of Food and Nutritional Sciences,University of Reading,Reading RG6 6AP,UK.
Glenn R
GR
Gibson
4Life Sciences Department,Health Sciences Research Centre,Whitelands College,University of Roehampton,London SW15 4JD,UK.
Adele
A
Costabile
D019342:Acetic Acid / Q000378:metabolism; D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D001644:Bifidobacterium / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D020148:Butyric Acid / Q000378:metabolism; D003106:Colon / Q000378:metabolism / Q000382:microbiology; D005232:Fatty Acids, Volatile / Q000378:metabolism*; D005243:Feces; D005285:Fermentation; D005690:Galactose / Q000494:pharmacology*; D000069196:Gastrointestinal Microbiome / Q000187:drug effects*; D006801:Humans; D007778:Lactobacillus / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D055432:Metabolomics; D009844:Oligosaccharides / Q000494:pharmacology*; D056692:Prebiotics; D011422:Propionates / Q000378:metabolism
D005232:Fatty Acids, Volatile; D009844:Oligosaccharides; D056692:Prebiotics; D011422:Propionates; D020148:Butyric Acid; C029658:propionic acid; D019342:Acetic Acid; D005690:Galactose
B-GOS Bimuno galacto-oligosaccharide; Bimuno® galacto-oligosaccharides; Fluorescence in situ hybridisation; GOS galacto-oligosaccharide; Microbiota composition; Prebiotic activity; SCFA